The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2025 / November / Understanding the Benefits of Gelatin and Collagen
Formulation Development & Clinical Small Molecules Sponsored

Understanding the Benefits of Gelatin and Collagen

Check out our interview from CPHI Frankfurt featuring GELITA’s Samy Jandall

11/27/2025 0 min read Video

Sponsored By

Share

What important roles do gelatin and collagen play in biomedical applications? And why are endotoxin controlled excipients so important? Find out in this interview with Samy Jandall, GVP Global Business Management at the GELITA Group.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Musings from The Power List: Fabian Gerlinghaus
Development & Clinical Cell & Gene Interviews
Musings from The Power List: Fabian Gerlinghaus

October 1, 2026

3 min read

Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made

 In vivo CAR‑T – Reimagining Immune Engineering with Direct Cell Reprogramming
Cell & Gene
In vivo CAR‑T – Reimagining Immune Engineering with Direct Cell Reprogramming

September 30, 2026

10 min read

How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy to new indications

How Companion Diagnostics Can Support Targeted Drug Launches
Development & Clinical Future of Pharma
How Companion Diagnostics Can Support Targeted Drug Launches

September 29, 2026

5 min read

Coordinated development and practical testing pathways can help ensure eligible patients are identified from the point of approval

Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169
Cell & Gene Industry News Development & Clinical
Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169

September 28, 2026

3 min read

Phase I study will test whether a targeted lentiviral vector can generate BCMA-directed CAR T cells inside patients with multiple myeloma

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: